
ZITUVIMET
SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Pharmacist's Verdict
This is a highly effective prescription-only medication for Type 2 diabetes, combining two proven drugs to lower blood sugar more effectively than either one alone.
Ingredient Analysis
Metformin Hydrochloride
Sitagliptin
Pros & Cons
Pros
- Combines two different medications into a single pill, making it easier to take.
- Targets blood sugar control through two separate mechanisms for better results.
- Low risk of causing dangerously low blood sugar (hypoglycemia) when used on its own.
- Metformin, one of the ingredients, is a trusted, first-choice drug for diabetes management.
Cons
- This is a prescription drug and is NOT available over-the-counter; it requires a doctor's diagnosis and supervision.
- Common side effects, especially when starting, include diarrhea, nausea, and stomach upset.
- Carries a risk for rare but serious side effects, including lactic acidosis (a buildup of acid in the blood) and pancreatitis (inflammation of the pancreas).
- Requires regular blood tests to monitor kidney function.
- Not suitable for patients with severe kidney disease.
Safety Information
Potential Side Effects
6 ADVERSE REACTIONS The following adverse reactions are also discussed elsewhere in the prescribing information: Lactic Acidosis [see Warnings and Precautions ( 5.1 )] Pancreatitis [see Warnings and Precautions ( 5.2 )] Heart Failure [see Warnings and Precautions ( 5.3 )] Acute Renal Failure [see Warnings and Precautions ( 5.4 )] Vitamin B12 Deficiency [see Warnings and Precautions ( 5.5 )] Hypoglycemia with Concomitant Use with Insulin or Insulin Secretagogues [see Warnings and Precautions ( 5.6 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.7 )] Severe and Disabling Arthralgia [see Warnings and Precautions ( 5.8 )] Bullous Pemphigoid [see Warnings and Precautions ( 5.9 )] Most common adverse reactions (incidence ≥5% of patients simultaneously started on sitagliptin and m…
Is ZITUVIMET safe for you?
See pregnancy, interactions, and common concerns answered in our pharmacist safety FAQ.
Read safety review →References
- 1.FDA Drug Label — ZITUVIMET
FDA DailyMed: ZITUVIMET · FDA
- 2.Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.
Zhang YS, Zheng YD, Yuan Y, et al., Frontiers in endocrinology, 2021 · PubMed
- 3.Clinical review: Drugs commonly associated with weight change: a systematic review and meta-analysis.
Domecq JP, Prutsky G, Leppin A, et al., The Journal of clinical endocrinology and metabolism, 2015 · PubMed
- 4.Drug-Induced Acute Pancreatitis: A Real-World Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database.
Li D, Wang H, Qin C, et al., Clinical pharmacology and therapeutics, 2024 · PubMed
- 5.Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Johnston R, Uthman O, Cummins E, et al., Health technology assessment (Winchester, England), 2017 · PubMed
- 6.Sitagliptin.
Lyseng-Williamson KA, Drugs, 2007 · PubMed